Joseph Duflot, MD
Nephrology · Fresno, CANPI 1467420679
Payments from drug & device makers
Across 229 payments — averaging $22.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Otsuka America Pharmaceutical, Inc.$564
- AstraZeneca$516
- Octapharma USA, Inc.$380
- Mallinckrodt Hospital Products Inc.$299
- Travere Therapeutics, Inc.$253
- plus $2K from 22 others
What the payments were for
- Food & beverage$5,071100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 66 | $1,221 |
| Otsuka America Pharmaceutical, Inc. | 20 | $564 |
| AstraZeneca(2 entities) | 26 | $516 |
| Octapharma USA, Inc. | 5 | $380 |
| Mallinckrodt Hospital Products Inc. | 10 | $299 |
| Travere Therapeutics, Inc. | 13 | $253 |
| Fresenius USA Marketing, Inc. | 9 | $220 |
| GSK | 10 | $185 |
| Bayer | 10 | $177 |
| Novartis | 9 | $152 |
| Boehringer Ingelheim | 5 | $140 |
| Baxter Healthcare | 1 | $125 |
| Akebia Therapeutics Inc | 6 | $123 |
| Calliditas Therapeutics US Inc. | 7 | $119 |
| Vifor Pharma, Inc. | 6 | $92 |
| Sanofi | 4 | $86 |
| Aurinia Pharma U.S., Inc. | 4 | $83 |
| Lilly USA, LLC | 4 | $64 |
| Ultragenyx Pharmaceutical Inc. | 3 | $59 |
| Kyowa Kirin, Inc. | 2 | $49 |
| Amicus Therapeutics, Inc. | 2 | $36 |
| Shield Therapeutics Inc | 1 | $28 |
| Shire North American Group Inc | 1 | $25 |
| Nxstage Medical, Inc. | 1 | $20 |
| ANI Pharmaceuticals, Inc. | 1 | $20 |
| Scpharmaceuticals Inc. | 1 | $18 |
| Mallinckrodt Enterprises LLC | 1 | $16 |
| Genentech USA, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,084 in reported general payments places this provider in the 70th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XphozahTenapanor Hcl | 70 | $197,566 |
| FarxigaDapagliflozin Propanediol | 89 | $133,085 |
| JardianceEmpagliflozin | 37 | $53,980 |
| KerendiaFinerenone | 45 | $46,881 |
| Sevelamer Carbonate | 196 | $44,521 |
| VelphoroSucroferric Oxyhydroxide | 16 | $40,187 |
| VeltassaPatiromer Calcium Sorbitex | 32 | $32,915 |
| LokelmaSodium Zirconium Cyclosilicate | 38 | $29,278 |
| AuryxiaFerric Citrate | 15 | $20,076 |
| ProsolParenteral Amino Acid 20% No.1 | 103 | $16,889 |
| EntrestoSacubitril/Valsartan | 17 | $13,396 |
| DapagliflozinDapagliflozin Propanediol | 18 | $13,338 |
| Cinacalcet Hcl | 38 | $10,416 |
| Calcium Acetate | 121 | $8,342 |
| ClinisolParenteral Amino Acid 15% No.5 | 44 | $4,892 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $516 | $162,363127 claims |
| Boehringer IngelheimJardiance | $140 | $53,98037 claims |
| BayerKerendia | $177 | $46,88145 claims |
| Fresenius USA Marketing, Inc.Velphoro | $220 | $40,18716 claims |
| Akebia Therapeutics IncAuryxia | $123 | $20,07615 claims |
| NovartisEntresto | $152 | $13,39617 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $20 | $1,10135 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,341 nephrology providers in California.
Other nephrology in Fresno
- Hemant DhingraFresno$569K
- Anjay RastogiLos Angeles$6.3M
- Aamir JamalSan Dimas$5.5M
- Mohamed El-ShahawyLos Angeles$4.4M
- Kalpesh PatelCalabasas$3.6M
- Jehad HaggiagiMission Hills$3.6M
- Malvin YanSouth Gate$3.3M
- Sohan DuaNorthridge$3.2M
- Richard LafayetteStanford$3M
- Anant DesaiGranada Hills$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.